In the present study, the mean increases reported in weight, BMI, and waist circumference after 12 months were comparable in naive patients starting abacavir/ lamivudine/dolutegraviror tenofovir alafenamide/emtricitabine/bictegravir.
Calza L, L.G. (2022). Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 89(3), 30-30 [10.1097/QAI.0000000000002861].
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir
Calza L;Verucchi G;Bon I;Lazzarotto T;Viale P
2022
Abstract
In the present study, the mean increases reported in weight, BMI, and waist circumference after 12 months were comparable in naive patients starting abacavir/ lamivudine/dolutegraviror tenofovir alafenamide/emtricitabine/bictegravir.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
AIDS 2022.pdf
accesso riservato
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per accesso riservato
Dimensione
384.9 kB
Formato
Adobe PDF
|
384.9 kB | Adobe PDF | Visualizza/Apri Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
